HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021

Dec 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-12-21

Reporting Person: Johnson Craig A (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-21	Common Stock	S	250	$9.7277	Disposed	2840	Direct
2021-12-22	Common Stock	A	10452	$0.00	Acquired	13292	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-22	Stock Option (Right to Buy)	$9.81	A	20903	Acquired	2031-12-22	Common Stock (20903)	Direct

Footnotes

F1: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of March 3, 2021. The shares were sold by Mr. Johnson to cover his estimated tax liability associated with the vesting of 750 restricted stock units (RSUs) on December 21, 2021.

F2: The range of sales prices received was $9.625 to $9.845. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.

F3: The shares were granted as restricted stock units which vest in full on December 22, 2022.

F4: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.